Abstract library

11 results for "CD117".
#450 Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors in Germany: First Results of a Multiinstitutional Cancer Registry
Introduction: Peptide receptor radionuclide therapy is an effective treatment option for patients with well-differentiated somatostatin receptor expressing neuroendocrine tumors. However, published data results mainly from retrospective monocentric studies.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof. Dr. Dieter Hörsch
#995 Neuroendocrine Tumor of the Appendix in Pregnancy
Introduction: Despite the fact the appendix is one of the rarest anatomical locations of neuroendocrine tumors (NETs) in the digestive system, the appendicular neuroendocrine tumor (A-NET) remains one of the most common tumors of the appendix.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Clinical cases/reports
Presenting Author: Andrejs Vanags
Authors: Vanags A, Simtniece Z, Strumfa I, ...
#1082 Characterization and Prognosis of Patients with Metastatic Lung Carcinoid Tumors
Introduction: Data on metastatic lung carcinoid tumors are limited.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: MD, PhD Thomas Walter
#1235 The Belgian DNET Registry: A Prospective, National, Web-Based Registry of Digestive Neuro-Endocrine Tumours (NET). Status After 2 Years of Inclusion.
Introduction: NET are rare neoplasms. The Belgian Group of Digestive Oncology created a web-based registry to have an overview on incidence, diagnosis and therapies performed in Belgian pts. The DNET registry was launched in 01/2012.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Prof. Dr. Ivan Borbath
Keywords: Registry, Belgium
#1332 NT-proBNP is Superior to ST2 and Galectin-3 Cardiac Markers in Identifying Carcinoid Heart Disease in Small Bowel NET Patients
Introduction: Carcinoid heart disease (CHD) develops in small bowel neuroendocrine tumour (sbNET) patients with carcinoid syndrome (CS). NT-proBNP (NTP) is suggested as the best current biomarker to screen and monitor for HF from CHD. A number of other markers, such as Galectin-3 (GAL3) and ST2 (or IL-1 R4), have been explored to diagnose and prognosticate in HF but have not been explored in NET patients with CS and CHD.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Biomarkers
Presenting Author: Dr Ron Basuroy
#1375 Merkel Cell Carcinoma of the Knee Treated with Somatostatin Analogue and Radiotherapy: A Case Report
Introduction: Merkel cell carcinoma (MCC) is a rare and aggressive primary cutaneous neuroendocrine malignancy. Chemotherapy with cisplatin (CDDP) and etoposide (VP16) is an effective treatment for metastatic MCC.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Ivana Puliafito
#1411 Role of Preoperative Computed Tomography (CT) in Diagnostics and Disease Stage of Small Bowel NEN: Correlation with Pathology Based on pTNM WHO 2010 Classification
Introduction: SbNEN are difficult to diagnose on standard CT without bowel preparation. Knowledge about specific radiological signs is essential.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Jakub Pałucki
#1780 PD-L1 Is Expressed in a Subset of Pancreatic Neuroendocrine Tumors (pNET)
Introduction: Programmed death 1 (PD-1) is an immune inhibitory receptor expressed on several immune cells, interacting with two ligands, PD-L1 and PD-L2. The former is expressed in many human cancers and is used as a selection criterion for indication of checkpoint inhibitor therapies. PD-L1 is also a potential target for checkpoint inhibitors in pNET therapy, however no data on prevalence of PD-L1 expression and potential associations to clinico-pathologic features is available.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: MMed Charalampos Saganas
#1822 Heterogeneity of Type 1 Gastric Neuroendocrine Neoplasms
Introduction: Type 1 gastric Neuroendocrine Neoplasms (gNENs) are defined when atrophic body gastritis is associated. They are mostly multiple, small, with a low grade histology with low metastatic risk. Data on factors associated with malignant tumor behavior in these patients are scarce.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Doctor Maria Rinzivillo
Keywords: Gastric NEN, Grading
#2020 Expression of Somatostatin Receptors in Neuroendocrine Tumors of the Lungs with Various Degrees of Malignancy
Introduction: Diagnostics and management of patients with neuroendocrine tumors of the lung requires an individual approach
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: MD Larisa Gurevich